首页> 外文期刊>Frontiers in Pharmacology >Docking Studies and Biological Evaluation of a Potential β-Secretase Inhibitor of 3-Hydroxyhericenone F from Hericium erinaceus
【24h】

Docking Studies and Biological Evaluation of a Potential β-Secretase Inhibitor of 3-Hydroxyhericenone F from Hericium erinaceus

机译:猴头猴3-羟烯酮F的潜在β-分泌酶抑制剂的对接研究和生物学评价

获取原文
           

摘要

Alzheimer’s disease (AD) is the most common neurodegenerative disorder, affecting approximately more than 5% of the population worldwide over the age 65, annually. The incidence of AD is expected to be higher in the next 10 years. AD patients experience poor prognosis and as a consequence new drugs and therapeutic strategies are required in order to improve the clinical responses and outcomes of AD. The purpose of the present study was to screen a certain number of potential compounds from herbal sources and investigate their corresponding mode of action. In the present study, the learning and memory effects of ethanol:water (8:2) extracts from Hericium erinaceus were evaluated on a dementia rat model. The model was established by intraperitoneal injection of 100 mg/kg/d D-galactose in rats. The results indicated that the extracts can significantly ameliorate the learning and memory abilities. Specific active ingredients were screened in vivo assays and the results were combined with molecular docking studies. Potential receptor–ligand interactions on the BACE1-inhibitor namely, 3-Hydroxyhericenone F (3HF) were investigated. The isolation of a limited amount of 3HF from the fruit body of H. erinaceus by chemical separation was conducted, and the mode of action of this compound was verified in NaN3-induced PC12 cells. The cell-based assays demonstrated that 3HF can significantly down-regulate the expression of BACE1 (p < 0.01), while additional AD intracellular markers namely, p-Tau and Aβ1-42 were further down-regulated (p < 0.05). The data further indicate that 3HF can ameliorate certain mitochondrial dysfunction conditions by the reversal of the decreasing level of mitochondrial respiratory chain complexes, the calcium ion levels ([Ca2+]), the inhibiton in the production of ROS, the increase in the mitochondrial membrane potential and ATP levels, and the regulation of the expression levels of the genes encoding for the p21, COX I, COX II, PARP1, and NF-κB proteins. The observations suggest the use of H. erinaceus in traditional medicine for the treatment of various neurological diseases and render 3HF as a promising naturally occurring chemical constituent for the treatment of AD via the inhibition of the β-secretase enzyme.
机译:阿尔茨海默氏病(AD)是最常见的神经退行性疾病,每年影响全球65岁以上人口的5%以上。预计未来10年内AD的发病率会更高。 AD患者的预后较差,因此需要新药和治疗策略以改善AD的临床反应和结果。本研究的目的是从草药中筛选出一定数量的潜在化合物,并研究其相应的作用方式。在本研究中,在痴呆大鼠模型上评估了猴头菇乙醇:水(8:2)提取物的学习和记忆作用。通过大鼠腹膜内注射100 mg / kg / d D-半乳糖建立模型。结果表明,提取物可以显着改善学习和记忆能力。在体内测定中筛选了特定的活性成分,并将结果与​​分子对接研究相结合。研究了在BACE1抑制剂3-羟基羟乙基烯酮F(3HF)上潜在的受体-配体相互作用。通过化学分离从芥子菊的子实体中分离出有限量的3HF,并在NaN3诱导的PC12细胞中验证了该化合物的作用方式。基于细胞的分析表明3HF可以显着下调BACE1的表达(p <0.01),而其他AD细胞内标志物p-Tau和Aβ1-42则进一步下调(p <0.05)。数据进一步表明3HF可通过逆转线粒体呼吸链复合物水平的降低,钙离子水平([Ca2 +]),ROS产生的抑制因子,线粒体膜电位的增加而改善某些线粒体功能障碍的状况。和ATP水平,以及编码p21,COX I,COX II,PARP1和NF-κB蛋白的基因的表达水平的调节。观察结果表明,在传统医学中使用贺兰氏可用于治疗各种神经系统疾病,并通过抑制β-分泌酶将3HF用作治疗AD的有希望的天然化学成分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号